Former Super Bowl Champ to Appear on ESPN Panel Focused on Will Smith’s New Film Concussion, Discussing Traumatic Brain Injuries and Web Site www.TreatCTE.org
NEW YORK, Dec. 18, 2015 (GLOBE NEWSWIRE) – Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public that investment portfolio company KannaLife Sciences’ spokesman and former NFL star Marvin Washington will be appearing on ESPN’s Outside the Lines Friday, December 18, from 2:30pm-3pm ET.
Washington will appear on a special panel of former NFL players to discuss the upcoming Sony Pictures film Concussion starring Will Smith, who plays Dr. Bennet Omalu, the forensic pathologist that discovered the brain disease Chronic Traumatic Encephalopathy (CTE) in a deceased Pittsburgh Steelers football player.
The former Super Bowl champ with the Denver Broncos will also discuss the new “Show Your Green” video public service announcement (PSA) campaign launched by KannaLife to create awareness of (CTE), explain what the disease is, and who it impacts. MJNA directly owns 16.70% of KannaLife’s capital stock.
Anyone interested in how to make a difference through medical research and developing a solution for CTE can visit the new web site www.treatCTE.org. There, visitors can “Show Your Green” by sharing a photo donning green “eye black” along with the PSA video within their social networks.
From 1988 to 1999, Washington played in 155 games over 11 seasons in the NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49’ers and as a member of the 1998 Superbowl champion Denver Broncos. Having been diagnosed with three known concussions and a countless number of subconcussions, the former NFL star is very passionate about helping individuals who are battling the debilitating and often deadly effects of CTE.
KannaLife Sciences, Inc. (“KannaLife”), an MJNA portfolio company, is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife currently holds two licenses with National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by KannaLife to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE): http://www.google.com/patents/US6630507. KannaLife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.
About KannaLife Sciences, Inc.
KannaLife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, on KannaLife, please visit the company’s website at: www.kannalife.com.
About Medical Marijuana Inc.
The mission of Medical Marijuana, Inc. (OTC Pink:MJNA) is to be the premier cannabis and hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information on Medical Marijuana, Inc., please visit the company’s website at: www.medicalmarijuanainc.com
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Their companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: